Tag: Novartis

Novartis commits to addressing racial disparities in breast cancer screening, treatment, and care

Stuart Mitchell

Novartis has announced the launch of More Than Just Words, a multiyear commitment to promote health equity in breast cancer care, where there is significant unmet need. Black women under the age of 35 are diagnosed with breast cancer at twice the rate of white women the same age. During 2020, breast cancer became the most commonly diagnosed cancer worldwide, while at the same time, breast cancer screenings overall have decreased drastically. With COVID-19 and breast cancer disproportionately impacting women of color and drops in screenings threatening timely diagnoses and…

Read More

Novartis Releases 2020 Novartis in Society Report to Share Progress on Key Environmental, Social and Governance (ESG) Topics

Stuart Mitchell

For the eighth consecutive year, Novartis is publishing an annual Novartis in Society ESG report. The report has been prepared in accordance with the GRI Standards: Core option.  It supplements the “Build trust with society” section in the 2020 Novartis Annual Review and the 2020 Novartis Annual Report. The report is divided into four chapters based on our material clusters and the corporate priorities for building trust with society: holding ourselves to high ethical standards; being part of the solution on pricing and access; addressing global health challenges; and being a…

Read More

Novartis Renews WHO Medicine Donation Pledge With Aim of Ending Leprosy

Stuart Mitchell

A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025. Widespread use of MDT has led to a 95% reduction in leprosy prevalence world-wide since its introduction the 1980s, though more than 200,000 cases are still seen every year.1 Despite the huge impact of MDT,…

Read More

Novartis and the Bill & Melinda Gates Foundation Collaborate to Discover and Develop an Accessible in Vivo Gene Therapy for Sickle Cell Disease

Stuart Mitchell

Novartis has announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD). The project brings together Novartis drug discovery and gene therapy expertise with the Gates Foundation’s charitable objectives to expand access to healthcare in low-resource settings in an effort to address this potentially life-threatening genetic disease. “Existing gene therapy approaches to sickle cell disease…

Read More

Novartis Set to Achieve 100% Renewable Electricity in Its European Operations

Stuart Mitchell

Novartis has announced the signature of five virtual power purchase agreements (VPPAs), which are expected to collectively add more than 275 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve 100% renewable electricity in its European operations through VPPAs.  “At Novartis, environmental sustainability is aligned with our purpose to reimagine medicine to improve and extend people’s lives,” said Montse Montaner, Chief Sustainability Officer at Novartis. “Energy efficiency and renewable energy solutions are the cornerstones of our strategy for reducing emissions.…

Read More